Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIP-modified allogeneic induced pluripotent stem cells
- Development stage
- Unknown
- Lead developer
- Sana Biotechnology
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Injection
01
Overview
Sana Biotechnology's HIP-modified allogeneic induced pluripotent stem cells (HIP iPSCs) are a platform of genetically engineered cells designed to evade the host immune system. The modification involves the depletion of HLA class I and II molecules (via B2M and CIITA knockout) to prevent T-cell recognition and the overexpression of CD47 to inhibit innate immune rejection by macrophages and NK cells. This "hypoimmune" profile allows for the creation of off-the-shelf, allogeneic cell therapies that can survive and function in immunocompetent recipients without the need for systemic immunosuppression. The technology is being applied to various therapeutic areas, including the generation of pancreatic islet cells for Type 1 diabetes and cardiomyocytes for heart failure.
- Other names
- hypoimmune induced pluripotent stem cellsHIP iPSCsgenetically engineered induced pluripotent stem cells
02
Targets
CD47 (Cluster of Differentiation 47)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on HIP-modified allogeneic induced pluripotent stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIP-modified allogeneic induced pluripotent stem cells.